米非司酮对子宫肌瘤组织内雌和孕激素受体及其表皮生长因子受体的影响分析

Analysis of the effect of mifepristone on the estrogen receptor, progesterone receptor and epidermal growth factor receptor in uterine leiomyoma tissues

目的探讨米非司酮对子宫肌瘤组织内雌、孕激素受体（ER、PR）和表皮生长因子受体（ECFR）的影响。方法将2014—01-01—2015-01—31诸城市人民医院收治40例子宫肌瘤患者随机分为研究组和对照组，每组20例。研究组给予米非司酮治疗，对照组不给予米非司酮治疗，测定并比较2组患者子宫肌瘤组织内雌和ER、PR含量，以及患者ECFR水平。结果治疗后研究组子宫肌瘤、PR和ECFP明显低于对照组，P〈0．05。2组ER含量比较差异无统计学意义，P〉0.05。结论米非司酮主要是通过抑制子宫肌瘤细胞PR和表皮生长因子受体表达，而不是通过抑制子宫肌瘤细胞ER来控制子宫肌瘤的生长。

OBJECTIVE To investigate the effect of mifepristone on the estrogen, progesterone receptor （PR, ER） and epidermal growth factor receptor （ECFR） in uterine leiomyoma tissues. METHODS The 40 cases of uterine fibroids were divided randomly into control group and study group, 20 cases in each group, the study group given mifepristone treatment, control group was not given to mifepristone treatment, were determined and compared two groups of patients with uterine leiomyoma estrogen and ER and PR contents, and patients with ECFR level. RESULTS The uterine fi- broids, ECFP and PR in the research group were significantly lower than those in the control group （P^0.05）, and the contents of ER in the two groups were compared （P〈0.05）, and there was no significant. CONCLUSION Mifepristone in the son is mainly through the inhibition of uterine fibroids cells PR and epidermal growth factor receptor expression, rather than by inhibiting uterine fibroids ER to control the growth of uterine fibroids.